Immunocore Files 8-K with Corporate Updates

TL;DR

Immunocore filed an 8-K on 4/5/24 updating corporate info. Nothing major.

AI Summary

Immunocore Holdings plc filed an 8-K on April 5, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY, and its telephone number is +44 1235 438600. The company was formerly known as Immunocore Ltd until April 12, 2016.

Why It Matters

This filing provides essential corporate information and updates for Immunocore Holdings plc, including its registered address and former company name, which is important for investors and stakeholders tracking the company's official details.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain any material non-public information that would significantly impact the company's risk profile.

Key Players & Entities

• Immunocore Holdings plc (company) — Registrant
• April 5, 2024 (date) — Date of Report
• 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY (location) — Principal executive offices
• +44 1235 438600 (phone_number) — Registrant's telephone number
• Immunocore Ltd (company) — Former company name
• April 12, 2016 (date) — Date of name change

FAQ

Filing Documents

• ny20026042x2_8k.htm (8-K) — 30KB
• ny20026042x2_ex5-1.htm (EX-5.1) — 107KB
• ny20026042x2_ex5-1img01.jpg (GRAPHIC) — 86KB
• 0001140361-24-018342.txt ( ) — 410KB
• imcr-20240405.xsd (EX-101.SCH) — 4KB
• imcr-20240405_lab.xml (EX-101.LAB) — 21KB
• imcr-20240405_pre.xml (EX-101.PRE) — 16KB
• ny20026042x2_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. On April 5, 2024, Immunocore Holdings plc (the " Company ") filed a prospectus supplement (the " Prospectus Supplement ") to its effective registration statement on Form S-3ASR (File No. 333-278120) (the " Registration Statement ") filed with the U.S. Securities and Exchange Commission, under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholder named therein of up to 1,220,063 American Depositary Shares (the " Shares "), each representing the right to receive one ordinary share with a nominal value of 0.002 per share, of the Company. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Cooley (UK) LLP, regarding the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 5.1 Opinion of Cooley (UK) LLP. 23.1 Consent of Cooley (UK) LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: April 5, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR